Anika Therapeutics (ANIK) Competitors $8.35 -0.42 (-4.79%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$12.00 +3.65 (+43.71%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ANIK vs. ANVS, CERS, OSUR, UTMD, WST, COO, ALGN, MMSI, HAE, and ICUIShould you be buying Anika Therapeutics stock or one of its competitors? The main competitors of Anika Therapeutics include Annovis Bio (ANVS), Cerus (CERS), OraSure Technologies (OSUR), Utah Medical Products (UTMD), West Pharmaceutical Services (WST), Cooper Companies (COO), Align Technology (ALGN), Merit Medical Systems (MMSI), Haemonetics (HAE), and ICU Medical (ICUI). These companies are all part of the "medical" sector. Anika Therapeutics vs. Its Competitors Annovis Bio Cerus OraSure Technologies Utah Medical Products West Pharmaceutical Services Cooper Companies Align Technology Merit Medical Systems Haemonetics ICU Medical Annovis Bio (NYSE:ANVS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment. Which has preferable valuation & earnings, ANVS or ANIK? Annovis Bio has higher earnings, but lower revenue than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$24.59M-$2.16-1.26Anika Therapeutics$119.91M1.00-$56.38M-$4.15-2.01 Do institutionals and insiders hold more shares of ANVS or ANIK? 15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by insiders. Comparatively, 9.6% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts prefer ANVS or ANIK? Annovis Bio currently has a consensus target price of $18.00, suggesting a potential upside of 559.34%. Anika Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 115.57%. Given Annovis Bio's higher possible upside, equities analysts plainly believe Annovis Bio is more favorable than Anika Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Anika Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more risk & volatility, ANVS or ANIK? Annovis Bio has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Does the media refer more to ANVS or ANIK? In the previous week, Anika Therapeutics had 15 more articles in the media than Annovis Bio. MarketBeat recorded 15 mentions for Anika Therapeutics and 0 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.67 beat Anika Therapeutics' score of -0.22 indicating that Annovis Bio is being referred to more favorably in the media. Company Overall Sentiment Annovis Bio Positive Anika Therapeutics Neutral Is ANVS or ANIK more profitable? Annovis Bio has a net margin of 0.00% compared to Anika Therapeutics' net margin of -48.99%. Anika Therapeutics' return on equity of -10.97% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A -300.56% -193.50% Anika Therapeutics -48.99%-10.97%-8.51% SummaryAnnovis Bio beats Anika Therapeutics on 9 of the 15 factors compared between the two stocks. Get Anika Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIK vs. The Competition Export to ExcelMetricAnika TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$126.45M$3.07B$5.59B$9.53BDividend YieldN/A2.41%4.73%4.14%P/E Ratio-2.0117.5328.9123.88Price / Sales1.00313.17448.7998.82Price / Cash91.9442.6035.6858.35Price / Book0.827.828.165.60Net Income-$56.38M-$54.52M$3.25B$265.26M7 Day Performance3.09%2.86%1.15%-0.14%1 Month Performance-25.88%17.29%8.25%6.08%1 Year Performance-67.97%13.27%29.18%24.22% Anika Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIKAnika Therapeutics4.4266 of 5 stars$8.35-4.8%$18.00+115.6%-67.6%$126.45M$119.91M-2.01300Positive NewsANVSAnnovis Bio2.0197 of 5 stars$2.68+6.8%$18.00+571.6%-67.5%$48.91MN/A-1.243Upcoming EarningsCERSCerus2.6207 of 5 stars$1.30+2.4%$3.50+169.2%-42.3%$242.77M$180.27M-13.00290News CoveragePositive NewsEarnings ReportOSUROraSure Technologies2.1428 of 5 stars$3.12+3.7%$3.00-3.8%-26.2%$225.15M$185.83M-7.43840Trending NewsUTMDUtah Medical Products3.1945 of 5 stars$56.78+3.3%N/A-13.6%$178.49M$40.90M15.18180Dividend AnnouncementWSTWest Pharmaceutical Services4.5954 of 5 stars$238.34-0.4%$320.71+34.6%-20.6%$17.20B$2.89B35.6810,600Positive NewsShort Interest ↑COOCooper Companies3.2611 of 5 stars$71.45+0.8%$96.73+35.4%-23.9%$14.17B$3.90B34.6816,000ALGNAlign Technology4.9446 of 5 stars$137.77+0.9%$215.00+56.1%-32.8%$9.90B$4.00B23.2320,945Trending NewsEarnings ReportBuyback AnnouncementMMSIMerit Medical Systems4.5854 of 5 stars$85.38+0.7%$107.00+25.3%-3.4%$5.02B$1.36B43.347,400Earnings ReportHAEHaemonetics4.864 of 5 stars$76.26+2.0%$97.30+27.6%-12.1%$3.59B$1.36B23.043,023Positive NewsUpcoming EarningsICUIICU Medical4.6714 of 5 stars$130.06+2.1%$192.67+48.1%+7.8%$3.14B$2.38B-33.9615,000Positive NewsUpcoming Earnings Related Companies and Tools Related Companies Annovis Bio Alternatives Cerus Alternatives OraSure Technologies Alternatives Utah Medical Products Alternatives West Pharmaceutical Services Alternatives Cooper Companies Alternatives Align Technology Alternatives Merit Medical Systems Alternatives Haemonetics Alternatives ICU Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIK) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANIK Stock Alerts